AzTrials
AzTrials

Migraine, HemicraniaPhase 4MOHCNCT04410536

Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency

A Phase 4 study testing Symptomatic drugs, Bridge therapy and Mindfulness program in people with Migraine, Hemicrania, run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse, but it is also confirmed that patients… Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Migraine, Hemicrania
What is being tested?
Symptomatic drugs, Bridge therapy and Mindfulness program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteItaly
Study dates
15 Jun 2020to 31 Jul 2022
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • age >18 yrs diagnosis of MOH and CM (1) written informed consent

Who cannot join

  • co-existent severe medical or psychiatric illnesses, documented by specific previous diagnoses seizures use of opioids

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Fondazione IRCCS Istituto Neurologico C. Besta, Neuroalgology Unit

    Milan, Milano, 20133

Other trials in Italy

About this study

Official title: Home-withdrawal Program Combined With Behavioural Approach in Patients With Medication Overuse Headache During Covid-19 Emergency: Incidence of Relapses in Overuse and Changes in Impact at One Year Follow up

Medication Overuse Headache (MOH) is a disabling condition that affects the 2% of migraine population. Medication overuse (MO) makes this condition very difficult to treat. The literature of the last decades confirm the efficacy of withdrawal for patients with medication overuse, but it is also confirmed that patients have to be carefully followed after withdrawal to avoid relapses and to improve the clinical benefit of the therapeutic approach. Clinical results can be improved when traditional therapies are combined with behavioral approaches in particular mindfulness, that help patient to become more conscious about their symptoms and able to manage pain without medication. As the emergency situation due to the Corona-virus pandemic phenomenon in Italy, the regular clinical practice adopted for patients with CM-MO has changed in the last weeks: patients cannot come to the hospital for the withdrawal iv therapy and for regular follow up as the reduced mobility due to the emergency in particular in the Lombardia region, but all over Italy. So the investigators propose a pilot study to enforce the application of a Home-program for the withdrawal procedure for patients and the use of technology like smartphone and video calls so that patients can continue to be followed in their therapeutic process by using behavioral support and mindfulness practice. Patients will perform the withdrawal program at home, by oral administration of therapies, with specific instructions and education. Also the information for behavioral approach and mindfulness practice will be given, to use every day at home. Daily standardized mindfulness sessions of 12 minutes on their smartphone will be combined with weekly video-call to evaluate the clinical condition and to encourage the use strategies for pain management. Face-to-face visits at the follow up every three months will be scheduled. This modality will allow the patients to continue their therapeutic process and to be regularly followed during the one year after withdrawal.

Read the detailed description

Background and significance Medication Overuse Headache (MOH) is a disabling pain syndrome with a prevalence of 2% in the general population, and which affects patients suffering from primary headaches, mainly those with Chronic Migraine (CM). This condition is very difficult to treat. The literature of the last decades confirmed the need to stop overuse through withdrawal (or detoxification programs) as an essential step in the treatment strategy , and high rates of successful outcomes are reported by several studies and reviews, although not all patients receiving treatment are able to stop MO or to reduce significantly the frequency of headaches. Remission rates range from 60% to 83% in studies with a 1-year follow-up, with an average relapse rate into MOH of 32.8% in a review on several studies from different countries, which is similar to the relapse into CM of 21.5% and into MOH of 33.9% found in a sample from our group . Literature data showed that patients need to be carefully followed after withdrawal to avoid relapses in overuse and to improve the clinical benefit, adding anti-migraine prophylaxi . Furthermore, different clinical experiences confirmed the effectiveness of interventions based on out-patient withdrawal programs and education and support to the correct use of medications to patients, and published evidence - also from our research group - supports the role of standardized behavioural approaches . The aspect of feasibility of these treatments is not regularly reported in published studies, but it can be estimated that a proportion of patients discontinue the treatment protocols, with a drop-out rate around 15-20% at one year from withdrawal., as it was 11% after 6 months, and 18% after 1 year in the seminal study by Katsarawa et al, and 9% after one year from withdrawal in a previous study from our research group . According to our protocols at the Headache Center, the withdrawal program is performed at hospital, either in an in-patient setting or in day-hospital setting. This program includes abrupt interruption of the overused drugs, intravenous therapy, educational support, rescue treatments for severe headaches, and prescription of a specific pharmacological prophylaxis for migraine prevention. Furthermore, standardized behavioural therapies are used during the treatment period, and during the follow up, particularly by approaches based on mindfulness practice - which usually delivered in groups of 4 - 8 patients . This approach may be particularly useful in helping patients to obtain a better outcome. All the above discussed considerations are even more relevant in this emergency situation due to the Corona-virus pandemic phenomenon in Italy, with its consequences on mobility of patients and clinical practice. In order to promote different modalities to respond to the needs of patients suffering from this disabling condition during the emergency, exercise-based telemedicine and smartphone applications seem very appropriate, as they have been recently tested in the management of chronic pain conditions . This preliminary study will be performed considering that the Covid-19 emergency reduced significantly our possibility to hospitalize patients for withdrawal treatments as well as the mobility of patients, particularly those living in other Italian regions than Lombardy, and in view of providing an effective and somewhat innovative treatment program for MOH and CM patients. The proposed treatment intervention is based on our experience, and on published reports, but it specifically includes a home based withdrawal program, several visits performed as Video calls, and educational and support strategies aimed to develop skills to reduce overuse and to cope with pain by a standardized behavioural approach based on mindfulness - which will be delivered mainly by telemedicine and smartphone applications. The aim of this pilot study is to assess the feasibility and the effectiveness at long-term on relevant outcomes of a specific protocol, designed to be appropriate during the emergency situation due to COVID-19 epidemic, by an approach that is alternative to current practice, particularly as far as avoiding the need for hospitalization, reducing face-to-face hospital visits taking advantage of facilities offered by new technologies, besides including innovative and emerging treatment choices, namely a behavioural approach base on mindfulness.

Being tested
Symptomatic drugs, Bridge therapy, Mindfulness program
Medical subject headings
Migraine Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Symptomatic drugsDrug

    indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide

  • Bridge therapyDrug

    prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day

  • Mindfulness programBehavioural

    home based withdrawal program

Study groups in NCT04410536
Study groupRoleWhat they receive
Symptomatic drugs - bridge theray - mindfuOther1. abrupt withdrawal of overuse symptomatic drugs, with possibility to use indomethacin suppository 50-100 mg or an oral triptan, on maximum 3 days/10 days, only in case of very severe headache- and to use metoclopramide i.m. injection in case of vomiting; 2. oral administration of a bridge therapy to reduce the withdrawal symptoms and rebound headache (prednisone 25 mg , 2 tablets after breakfast for 5 days, one tablet for 3 days, half tablet for 2 days ; bromazepam 1.5 mg, 1 tablet after breakfast, lunch and dinner for every day; pantoprazole 40 mg, 1 tablet after dinner every day); 3. mindfulness practice daily with standard sessions by smartphone 6 minutes per day.
Receives: Drug: Symptomatic drugs; Drug: Bridge therapy; Behavioral: Mindfulness program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Drop out rates

    Drop-out rates after withdrawal treatment

    Measured: at 12 months

Secondary outcomes (1)
  1. Absence of Medication Overuse Headache (MOH)

    Percentages of patients with absence of Medication Overuse Headache

    Measured: at 12 months from withdrawal program (assessed by Daily Diary Card)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jun 2020
  2. Study start15 Jun 2020
  3. Primary completion31 Dec 2021
  4. Study completion31 Jul 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
withdrawal program will be performed at home
Masking
None (open label)
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04410536
Sponsor's protocol ID
MOH
Acronym
MOHC
Status last verified
Jan 2025
First submitted
25 May 2020
Last updated
23 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Symptomatic drugs, Bridge therapy and Mindfulness program in people with Migraine, Hemicrania, run by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Drop out rates (time frame: at 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in